Analyst firms · Leerink Partners · FDMT

Leerink Partners FDMT price target and rating history

4D Molecular Therapeutics Inc. (FDMT) · Health Care

Leerink Partners rates 4D Molecular Therapeutics Inc. (FDMT) Outperform with a $24 price target, as of its latest action on Oct 18, 2023. It has published 3 rating actions on FDMT since January 2022, including 1 upgrade and 1 downgrade. Across 3 firms with a FDMT price target in the last 12 months, the median target is $33.

Current rating
Outperform
Price target
$24
Median target, all firms
$33
Actions on FDMT
3

Leerink Partners price target on FDMT

$30$21$122023202420252026
Leerink Partners price target on FDMT, each point a stated target, January 2022 to October 2023.

Every Leerink Partners rating on FDMT

How other firms rate FDMT

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Cantor FitzgeraldOverweight$20Sep 14, 2026
B. Riley SecuritiesBuy$37Jul 31, 2026
BarclaysOverweight$33Jan 28, 2026

Questions about Leerink Partners and FDMT

What is Leerink Partners's price target for FDMT?
Leerink Partners's latest stated price target for 4D Molecular Therapeutics Inc. (FDMT) is $24, from its action on Oct 18, 2023.
What is Leerink Partners's rating on FDMT?
Leerink Partners rates FDMT Outperform, a bullish rating, as of Oct 18, 2023.
When did Leerink Partners last change its view on FDMT?
On Oct 18, 2023, Leerink Partners upgrades to Outperform from Market Perform, price target $24.
How does Leerink Partners's FDMT target compare with other analysts?
Across 3 firms with a FDMT price target in the last 12 months, the median target is $33.

More FDMT rating histories

All Leerink Partners ratingsFDMT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.